DOCSLIB.ORG

Signal Transducer Glycoprotein 130 Extracellular Domains for Activation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Signal Transducer Glycoprotein 130 Extracellular Domains for Activation Importance of the Membrane-Proximal Extracellular Domains for Activation of the Signal Transducer Glycoprotein 130 This information is current as Ingo Kurth, Ursula Horsten, Stefan Pflanz, Andreas of September 28, 2021. Timmermann, Andrea Küster, Heike Dahmen, Ingrid Tacken, Peter C. Heinrich and Gerhard Müller-Newen J Immunol 2000; 164:273-282; ; doi: 10.4049/jimmunol.164.1.273 http://www.jimmunol.org/content/164/1/273 Downloaded from References This article cites 40 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/164/1/273.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Importance of the Membrane-Proximal Extracellular Domains for Activation of the Signal Transducer Glycoprotein 1301 Ingo Kurth, Ursula Horsten,2 Stefan Pflanz, Andreas Timmermann, Andrea Ku¨ster, Heike Dahmen, Ingrid Tacken, Peter C. Heinrich,3 and Gerhard Mu¨ller-Newen The transmembrane glycoprotein gp130 is the common signal transducing receptor subunit of the IL-6-type cytokines. The gp130 extracellular part is predicted to consist of six individual domains. Whereas the role of the three membrane-distal domains (D1–D3) in binding of IL-6 and IL-11 is well established, the function of the membrane-proximal domains (D4–D6) is unclear. Mapping of a neutralizing mAb to the membrane-proximal part of gp130 suggests a functional role of D4–D6 in receptor activation. Individual deletion of these three domains differentially interferes with ligand binding of the soluble and membrane- bound receptors. All deletion mutants do not signal in response to IL-6 and IL-11. The deletion mutants D4 and, to a lesser extent, D6 are still activated by agonistic monoclonal gp130 Abs, whereas the deletion mutant D5 does not respond. Because membrane- Downloaded from bound D5 binds IL-6/soluble IL-6R as does wild-type gp130, but does not transduce a signal in response to various stimuli, this domain plays a prominent role in coupling of ligand binding and signal transduction. Replacement of the fifth domain of gp130 by the corresponding domain of the homologous G-CSF receptor leads to constitutive activation of the chimera upon overex- pression in COS-7 cells. In HepG2 cells this mutant responds to IL-6 comparable to wild-type gp130. Our findings suggest a functional role of the membrane-proximal domains of gp130 in receptor activation. Thus, within the hematopoietic receptor family the mechanism of receptor activation critically depends on the architecture of the receptor ectodomain. The Journal of Immu- http://www.jimmunol.org/ nology, 2000, 164: 273–282. he coordination and regulation of immune responses is Subsequently, the activated Jaks phosphorylate tyrosine residues mainly mediated by cytokines that specifically bind to cell of the receptor. These phosphotyrosine residues are docking sites T surface receptors. Cytokine receptors are usually classi- for latent transcription factors of the STAT family, which also fied due to structural similarities. Class I cytokine receptors are become phosphorylated at the receptor. The phosphorylated characterized by the presence of at least one cytokine binding STATs dimerize and translocate into the nucleus to regulate target module (CBM)4 that consists of two fibronectin-type III-like gene expression (2). by guest on September 28, 2021 (FNIII) domains. The N-terminal domain contains a set of four Whereas the ectodomains of the receptors for growth hormone conserved cysteine residues, and the C-terminal domain contains a (GH), erythropoietin (Epo), or prolactin solely consist of a single WSXWS motif or a closely related sequence. Receptors belonging CBM, other members of the class I cytokine receptor family, such to this family are engaged by helical cytokines consisting of four as gp130, G-CSFR, or the leptin receptor show a more complex tightly packed a-helices (1). The cytoplasmic parts of cytokine architecture, which in respect to their biological functions is not receptors do not contain a kinase domain, but constitutively asso- understood (3). The glycoprotein gp130 is the common signal ciate with Janus tyrosine kinases (Jaks). Binding of the ligand transducing receptor subunit of the IL-6-type cytokines IL-6, IL- leads to receptor dimerization and juxtaposition of the associated 11, leukemia inhibitory factor (LIF), ciliary neurotrophic factor Jaks, which results in their activation by tyrosine phosphorylation. (CNTF), oncostatin M (OSM), and cardiotrophin-1 (4). The extra- cellular part of gp130 contains an Ig-like domain (D1) followed by a single CBM (D2 and D3) and three FNIII domains (D4, D5, and Institut fu¨r Biochemie, Rheinisch-Westfa¨lische Technische Hochschule Aachen, Aachen, Germany D6) (5). Signal transduction is achieved by either homodimeriza- tion of gp130 in response to IL-6 (6) and IL-11 (7) or heterodimer- Received for publication April 15, 1999. Accepted for publication October 8, 1999. ization of gp130 with the LIFR in response to LIF (8), CNTF (9), The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance OSM (8), or CT1 (10). Alternatively, OSM induces the het- with 18 U.S.C. Section 1734 solely to indicate this fact. erodimerization of gp130 with the recently cloned OSMR (11). 1 This work was supported by grants from the Deutsche Forschungsgemeinschaft The cytokines IL-6, IL-11, and CNTF alone do not efficiently en- (Bonn, Germany) and the Fonds der Chemischen Industrie (Frankfurt am Main, gage the signal transducing receptor chains. They first bind to their Germany). specific a receptors that can functionally be replaced by the re- 2 Current address: Institut fu¨r Experimentelle und Klinische Pharmakologie und Tox- ikologie der Universita¨t Erlangen-Nu¨rnberg, Universitätsstrasse 22, D-91054 Erlan- spective soluble counterparts lacking the transmembrane and cy- gen, Germany. toplasmic regions (12). In addition to at least one CBM, all recep- 3 Address correspondence and reprint requests to Dr. Peter C. Heinrich, Institut fu¨r tors involved in IL-6-type cytokine signaling contain an Ig-like Biochemie, Rheinisch-Westfa¨lische Technische Hochschule Aachen, Pauwelsstrasse domain located N-terminally of the most membrane-proximal 30, D-52057 Aachen, Germany. E-mail address: [email protected] CBM. Besides the Ig-like domain and CBM(s), those receptors 4 Abbreviations used in this paper: CBM, cytokine binding module; FNIII, fibronectin type III-like; Jak, Janus kinase; GH, growth hormone; GHR, GH receptor; Epo, eryth- triggering the cytoplasmic signal transduction cascade (gp130, ropoietin; EpoR, Epo receptor; G-CSFR, G-CSF receptor; LIF, leukemia inhibitory LIFR, and OSMR) all contain three additional membrane-proximal factor; LIFR, LIF receptor; CNTF, ciliary neurotrophic factor; OSM, oncostatin M; OSMR, OSM receptor; SIE, sis-inducible element; sIL-6, soluble IL-6; sgp130, sol- FNIII domains whose function is still unknown. Mutagenesis stud- uble gp130. ies using deletion mutants of gp130 revealed that the CBM of Copyright © 2000 by The American Association of Immunologists 0022-1767/00/$02.00 274 MEMBRANE-PROXIMAL DOMAINS OF gp130 gp130 as well as the Ig-like domain are required for the interaction plasmids were sequenced using an ABI Prism Automated sequencer (Per- with IL-6/IL-6R (13–15), IL-11/IL-11R (16), and OSM (17). A kin-Elmer, Norwalk, CT). For expression in HepG2 cells, the cDNAs were more detailed analysis of the binding epitope revealed that the subcloned into the expression vector pRcCMV. To express the deletion constructs and chimera in the context of CBM of gp130 binds the ligand in a way similar to the GH/GHR gp130g, respective cDNAs were subcloned into the vector pSVLEg-Yg440 interaction (15, 18). These findings were supported by the crystal (27) using the restriction endonucleases XhoI and BstEII. The resulting structure of the gp130 CBM (19) as well as the solution structure vector encodes the extracellular domain, the transmembrane, and a trun- of gp130-D3 (20). cated intracellular part of gp130 (containing boxes 1 and 2) fused to the IFN-g receptor motif YDKPH, which predominantly activates STAT1. For Ligand-induced dimerization of cytokine receptors is widely ac- construction of plasmids encoding the soluble gp130 proteins the deletion cepted as a prerequisite for receptor activation (21, 22). In this constructs were subcloned into a vector (pSVLsgp130-Flag) (18) encoding respect, the functional role of the membrane-proximal domains of the extracellular domain of gp130 fused to a Flag epitope at the C-terminus. gp130 (D4–D6) is not understood. Because these three domains represent a common structural feature of the signal transducing Transfection of cells IL-6-type cytokine receptors, D4–D6 of gp130 may be essential Plasmid DNA was transfected into Ba/F3 cells by electroporation. Twenty- for receptor activation. The studies presented here using deletion eight micrograms of the gp130 expression vector were coelectroporated m 3 6 mutants of gp130 reveal that the membrane-proximal domains with 2 g of pSV2neo into 3.5 10 cells in 0.8 ml of medium applying a single 70-ms pulse at 200 V.
Load more

Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Oncostatin M Exhibit Elevated Responsiveness to IL-31 Receptor
    IL-31 Receptor (IL-31RA) Knockout Mice Exhibit Elevated Responsiveness to Oncostatin M This information is current as Janine Bilsborough, Sherri Mudri, Eric Chadwick, Brandon of September 28, 2021. Harder and Stacey R. Dillon J Immunol 2010; 185:6023-6030; Prepublished online 18 October 2010; doi: 10.4049/jimmunol.0902769 http://www.jimmunol.org/content/185/10/6023 Downloaded from References This article cites 29 articles, 6 of which you can access for free at: http://www.jimmunol.org/content/185/10/6023.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology IL-31 Receptor (IL-31RA) Knockout Mice Exhibit Elevated Responsiveness to Oncostatin M Janine Bilsborough,1 Sherri Mudri,1 Eric Chadwick,2 Brandon Harder,3 and Stacey R. Dillon IL-31 signals through the heterodimeric receptor IL-31RA and oncostatin M receptor (OSMR), and has been linked with the development of atopic dermatitis, a Th2 cytokine-associated disease in humans.
    [Show full text]
  • TNF Decoy Receptors Encoded by Poxviruses
    pathogens Review TNF Decoy Receptors Encoded by Poxviruses Francisco Javier Alvarez-de Miranda † , Isabel Alonso-Sánchez † , Antonio Alcamí and Bruno Hernaez * Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Campus de Cantoblanco, Universidad Autónoma de Madrid, Nicolás Cabrera 1, 28049 Madrid, Spain; [email protected] (F.J.A.-d.M.); [email protected] (I.A.-S.); [email protected] (A.A.) * Correspondence: [email protected]; Tel.: +34-911-196-4590 † These authors contributed equally. Abstract: Tumour necrosis factor (TNF) is an inflammatory cytokine produced in response to viral infections that promotes the recruitment and activation of leukocytes to sites of infection. This TNF- based host response is essential to limit virus spreading, thus poxviruses have evolutionarily adopted diverse molecular mechanisms to counteract TNF antiviral action. These include the expression of poxvirus-encoded soluble receptors or proteins able to bind and neutralize TNF and other members of the TNF ligand superfamily, acting as decoy receptors. This article reviews in detail the various TNF decoy receptors identified to date in the genomes from different poxvirus species, with a special focus on their impact on poxvirus pathogenesis and their potential use as therapeutic molecules. Keywords: poxvirus; immune evasion; tumour necrosis factor; tumour necrosis factor receptors; lymphotoxin; inflammation; cytokines; secreted decoy receptors; vaccinia virus; ectromelia virus; cowpox virus Citation: Alvarez-de Miranda, F.J.; Alonso-Sánchez, I.; Alcamí, A.; 1. TNF Biology Hernaez, B. TNF Decoy Receptors TNF is a potent pro-inflammatory cytokine with a broad range of biological effects, Encoded by Poxviruses. Pathogens ranging from the activation of inflammatory gene programs to cell differentiation or 2021, 10, 1065.
    [Show full text]
  • Respiratory Viral Infection Function for Innate Defense Against Airway Epithelial Versus Immune Cell Stat1
    Airway Epithelial versus Immune Cell Stat1 Function for Innate Defense against Respiratory Viral Infection This information is current as Laurie P. Shornick, Audrey G. Wells, Yong Zhang, Anand of September 27, 2021. C. Patel, Guangming Huang, Kazutaka Takami, Moises Sosa, Nikhil A. Shukla, Eugene Agapov and Michael J. Holtzman J Immunol 2008; 180:3319-3328; ; doi: 10.4049/jimmunol.180.5.3319 Downloaded from http://www.jimmunol.org/content/180/5/3319 Supplementary http://www.jimmunol.org/content/suppl/2008/02/20/180.5.3319.DC1 Material http://www.jimmunol.org/ References This article cites 47 articles, 20 of which you can access for free at: http://www.jimmunol.org/content/180/5/3319.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 27, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Airway Epithelial versus Immune Cell Stat1 Function for Innate Defense against Respiratory Viral Infection1 Laurie P.
    [Show full text]
  • (CS-ⅣA-Be), a Novel IL-6R Antagonist, Inhibits IL-6/STAT3
    Author Manuscript Published OnlineFirst on February 29, 2016; DOI: 10.1158/1535-7163.MCT-15-0551 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Chikusetsusaponin Ⅳa butyl ester (CS-Ⅳa-Be), a novel IL-6R antagonist, inhibits IL-6/STAT3 signaling pathway and induces cancer cell apoptosis Jie Yang 1, 2, Shihui Qian 2, Xueting Cai 1, 2, Wuguang Lu 1, 2, Chunping Hu 1, 2, * Xiaoyan Sun1, 2, Yang Yang1, 2, Qiang Yu 3, S. Paul Gao 4, Peng Cao 1, 2 1. Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China 2. Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China 3. Shanghai Institute of Materia Medical, Chinese Academy of Sciences, Shanghai, 201203, China 4. Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY10065, USA Running title: CS-Ⅳa-Be, a novel IL-6R antagonist, inhibits IL-6/STAT3 Keywords: Chikusetsusaponin Ⅳ a butyl ester (CS- Ⅳ a-Be), STAT3, IL-6R, antagonist, cancer Grant support: P. Cao received Jiangsu Province Funds for Distinguished Young Scientists (BK20140049) grant, J. Yang received National Natural Science Foundation of China (No. 81403151) grant, and X.Y. Sun received National Natural Science Foundation of China (No. 81202576) grant. Corresponding author: Peng Cao Institute: Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, Jiangsu, China Mailing address: 100#, Shizi Street, Hongshan Road, Nanjing, Jiangsu, China Tel: +86-25-85608666 Fax: +86-25-85608666 Email address: [email protected] The first co-authors: Jie Yang and Shihui Qian The authors disclose no potential conflicts of interest.
    [Show full text]
  • Oncostatin M Is a Proinflammatory Mediator. in Vivo Effects Correlate with Endothelial Cell Expression of Inflammatory Cytokines and Adhesion Molecules
    Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. V Modur, … , G A Zimmerman, T M McIntyre J Clin Invest. 1997;100(1):158-168. https://doi.org/10.1172/JCI119508. Research Article Oncostatin M is a member of the IL-6 family of cytokines that is primarily known for its effects on cell growth. Endothelial cells have an abundance of receptors for oncostatin M, and may be its primary target. We determined if oncostatin M induces a key endothelial cell function, initiation of the inflammatory response. We found that subcutaneous injection of oncostatin M in mice caused an acute inflammatory reaction. Oncostatin M in vitro stimulated: (a) polymorphonuclear leukocyte (PMN) transmigration through confluent monolayers of primary human endothelial cells; (b) biphasic PMN adhesion through rapid P-selectin expression, and delayed adhesion mediated by E-selectin synthesis; (c) intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 accumulation; and (d) the expression of PMN activators IL-6, epithelial neutrophil activating peptide-78, growth-related cytokine alpha and growth-related cytokine beta without concomitant IL-8 synthesis. The nature of the response to oncostatin M varied with concentration, suggesting high and low affinity oncostatin M receptors independently stimulated specific responses. Immunohistochemistry showed that macrophage-like cells infiltrating human aortic aneurysms expressed oncostatin M, so it is present during a chronic inflammatory reaction. Therefore, oncostatin M, but not other IL-6 family members, fulfills Koch's postulates as an inflammatory mediator. Since its effects on endothelial cells differ significantly from established mediators like TNFalpha, it may uniquely contribute to the inflammatory cycle.
    [Show full text]
  • Flow Reagents Single Color Antibodies CD Chart
    CD CHART CD N° Alternative Name CD N° Alternative Name CD N° Alternative Name Beckman Coulter Clone Beckman Coulter Clone Beckman Coulter Clone T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells CD1a T6, R4, HTA1 Act p n n p n n S l CD99 MIC2 gene product, E2 p p p CD223 LAG-3 (Lymphocyte activation gene 3) Act n Act p n CD1b R1 Act p n n p n n S CD99R restricted CD99 p p CD224 GGT (γ-glutamyl transferase) p p p p p p CD1c R7, M241 Act S n n p n n S l CD100 SEMA4D (semaphorin 4D) p Low p p p n n CD225 Leu13, interferon induced transmembrane protein 1 (IFITM1). p p p p p CD1d R3 Act S n n Low n n S Intest CD101 V7, P126 Act n p n p n n p CD226 DNAM-1, PTA-1 Act n Act Act Act n p n CD1e R2 n n n n S CD102 ICAM-2 (intercellular adhesion molecule-2) p p n p Folli p CD227 MUC1, mucin 1, episialin, PUM, PEM, EMA, DF3, H23 Act p CD2 T11; Tp50; sheep red blood cell (SRBC) receptor; LFA-2 p S n p n n l CD103 HML-1 (human mucosal lymphocytes antigen 1), integrin aE chain S n n n n n n n l CD228 Melanotransferrin (MT), p97 p p CD3 T3, CD3 complex p n n n n n n n n n l CD104 integrin b4 chain; TSP-1180 n n n n n n n p p CD229 Ly9, T-lymphocyte surface antigen p p n p n
    [Show full text]
  • The Function of CD27 Costimulation in the Activation and Fate Decisions of CD8+ T Cells
    The function of CD27 costimulation in the activation and fate decisions of CD8+ T cells Han Dong Zhengzhou, Henan Province, China B.Sc, Zhejing University, 2009 A Dissertation presented to the Graduate Faculty of the University of Virginia in Candidacy for the Degree of Doctor of Philosophy Department of Experimental Pathology University of Virginia May 2015 ! i! Abstract CD8+ cytotoxic T lymphocytes are critical components of adaptive immunity against a variety of intracellular pathogens, and can play a key role in the control of tumors. Effective vaccination strategies against viral infections and tumors will likely require the development of potent CD8+ T cell responses, which are constituted by the expansion of robust primary CD8+ T cell populations and the establishment of long-lasting memory. Fully functional CD8+ T cell responses are highly dependent upon CD4+ helper T cells and Signal 3 inflammatory cytokine pathways. CD4+ T cells have been demonstrated to play a critical role in inducing the expression of CD70, the ligand for CD27, on dendritic cells. However, it is not clear to what extent the ‘help’ provided by CD4+ T cells is manifest via CD70, or how CD70-mediated stimulation of CD8+ T cells is integrated with signals that emanate from Signal 3 pathways, such as type-1 interferon (IFN-1) and IL- 12. In this work, by enforcing or abrogating CD27 function by genetic or protein intervention in murine models, we sought to identify the function of CD27 costimulation in the activation and fate decisions of CD8+ T cells, to determine the extent it resembles CD4+ T cell help, and how inflammation impacts the relative importance of CD70-CD27 interactions in CD8+ T cell primary responses and CD8+ T cell memory.
    [Show full text]
  • The Thrombopoietin Receptor : Revisiting the Master Regulator of Platelet Production
    This is a repository copy of The thrombopoietin receptor : revisiting the master regulator of platelet production. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/175234/ Version: Published Version Article: Hitchcock, Ian S orcid.org/0000-0001-7170-6703, Hafer, Maximillian, Sangkhae, Veena et al. (1 more author) (2021) The thrombopoietin receptor : revisiting the master regulator of platelet production. Platelets. pp. 1-9. ISSN 0953-7104 https://doi.org/10.1080/09537104.2021.1925102 Reuse This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Platelets ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/iplt20 The thrombopoietin receptor: revisiting the master regulator of platelet production Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae & Julie A. Tucker To cite this article: Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae & Julie A. Tucker (2021): The thrombopoietin receptor: revisiting the master regulator of platelet production, Platelets, DOI: 10.1080/09537104.2021.1925102 To link to this article: https://doi.org/10.1080/09537104.2021.1925102 © 2021 The Author(s).
    [Show full text]
  • Cytokine Profiling in Myeloproliferative Neoplasms
    cells Review Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants 1,2, , 1, 1 3 3 Elena Masselli * y , Giulia Pozzi y, Giuliana Gobbi , Stefania Merighi , Stefania Gessi , Marco Vitale 1,2,* and Cecilia Carubbi 1 1 Department of Medicine and Surgery, Anatomy Unit, University of Parma, Via Gramsci 14, 43126 Parma, Italy; [email protected] (G.P.); [email protected] (G.G.); [email protected] (C.C.) 2 University Hospital of Parma, AOU-PR, Via Gramsci 14, 43126 Parma, Italy 3 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; [email protected] (S.M.); [email protected] (S.G.) * Correspondence: [email protected] (E.M.); [email protected] (M.V.); Tel.: +39-052-190-6655 (E.M.); +39-052-103-3032 (M.V.) These authors contributed equally to this work. y Received: 1 September 2020; Accepted: 19 September 2020; Published: 21 September 2020 Abstract: Among hematologic malignancies, the classic Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) are considered a model of inflammation-related cancer development. In this context, the use of immune-modulating agents has recently expanded the MPN therapeutic scenario. Cytokines are key mediators of an auto-amplifying, detrimental cross-talk between the MPN clone and the tumor microenvironment represented by immune, stromal, and endothelial cells. This review focuses on recent advances in cytokine-profiling of MPN patients, analyzing different expression patterns among the three main Philadelphia-negative (Ph-negative) MPNs, as well as correlations with disease molecular profile, phenotype, progression, and outcome.
    [Show full text]
  • Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
    cells Review Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy Jan A. Rath and Caroline Arber * Department of oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne, Lausanne University Hospital and University of Lausanne, 1015 Lausanne, Switzerland * Correspondence: [email protected] Received: 18 May 2020; Accepted: 16 June 2020; Published: 18 June 2020 Abstract: T cell receptor (TCR)-based adoptive T cell therapies (ACT) hold great promise for the treatment of cancer, as TCRs can cover a broad range of target antigens. Here we summarize basic, translational and clinical results that provide insight into the challenges and opportunities of TCR-based ACT. We review the characteristics of target antigens and conventional αβ-TCRs, and provide a summary of published clinical trials with TCR-transgenic T cell therapies. We discuss how synthetic biology and innovative engineering strategies are poised to provide solutions for overcoming current limitations, that include functional avidity, MHC restriction, and most importantly, the tumor microenvironment. We also highlight the impact of precision genome editing on the next iteration of TCR-transgenic T cell therapies, and the discovery of novel immune engineering targets. We are convinced that some of these innovations will enable the field to move TCR gene therapy to the next level. Keywords: adoptive T cell therapy; transgenic TCR; engineered T cells; avidity; chimeric receptors; chimeric antigen receptor; cancer immunotherapy; CRISPR; gene editing; tumor microenvironment 1. Introduction Adoptive T cell therapy (ACT) with T cells expressing native or transgenic αβ-T cell receptors (TCRs) is a promising treatment for cancer, as TCRs cover a wide range of potential target antigens [1].
    [Show full text]
  • Kcnorman 1.Pdf
    A Computational Systems Approach to Elucidate New Mechanisms Involved in Progressive Lung Disease by Katy Norman A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Biomedical Engineering) in the University of Michigan 2020 Doctoral Committee: Assistant Professor Kelly Arnold, Chair Professor Jeffrey Curtis Professor Jennifer Linderman Professor Bethany Moore Professor David Sept Katy C. Norman [email protected] ORCID iD: 0000-0001-8841-0212 © Katy C. Norman 2020 Acknowledgements When I look back on myself in 2015 as I just entered the PhD program, I have to give a little laugh about all the surprises and changes that have happened along the way. I have grown more than I could ever have imagined – I have become so much more comfortable and confident in my communication skills, in my scientific skills, and in myself. These changes and this growth could not have happened without my huge support network, and I am honored to have the chance to thank everyone for what they have given me and for what they have helped me achieve. I would first like to thank my adviser, Kelly Arnold, for giving me a chance to try out computational systems biology research when I had absolutely no background in the field coming in. I appreciate how you were easily able to create a space where I felt comfortable to learn, to ask questions, and to make mistakes as I worked towards gaining expertise in this field. Thank you for always being there for me with extra support when my nerves were getting the best of me before big presentations or before a big deadline, and for supporting my involvement in activities outside of the lab as well.
    [Show full text]